<DOC>
	<DOCNO>NCT00003548</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness aminocamptothecin treat patient advanced cancer peritoneal cavity .</brief_summary>
	<brief_title>Aminocamptothecin Treating Patients With Advanced Cancer Peritoneal Cavity</brief_title>
	<detailed_description>OBJECTIVES : I . Determine qualitative quantitative toxicity intraperitoneal aminocamptothecin colloidal dispersion administer every 28 day 6 application 12 day period patient advance cancer confine peritoneal cavity . II . Determine maximum tolerate dose aminocamptothecin colloidal dispersion novel schedule patient population . III . Obtain pharmacological biochemical data potential predictor responses and/or drug toxicity patient . IV . Document presence degree antitumor activity regimen patient population . OUTLINE : This dose escalation study . Patients receive intraperitoneal aminocamptothecin colloidal dispersion ( 9-AC ) 30-60 minute 6 application 12 day period ( day 1 , 3 , 5 , 8 , 10 , 12 ) . Courses repeat every 28 day . Treatment continue 4-6 course absence unacceptable toxic effect disease progression . The dose 9-AC escalated cohort 3-6 patient maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow death . PROJECTED ACCRUAL : Approximately 15-20 patient accrue study within 18 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced malignancy involve peritoneal cavity , exclude leukemia lymphoma Patients ovarian cancer must receive prior standard therapy Predominantly small tumor metastasis less 1.0 cm diameter include : Ovarian cancer epithelial histology Other gynecological tumor Breast cancer Gastric cancer Colorectal cancer Appendiceal cancer Pancreatic cancer Unknown primary cancer Other malignancy predominantly intraperitoneal manifestation No extensive intraperitoneal adhesion easily lysed laparoscopically laparotomy No symptomatic disease outside peritoneal cavity Asymptomatic disease outside peritoneum consider ( e.g. , bone lesion ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL AST great 2 time upper limit normal Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas and/or mitomycin ) Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV anal cancer</keyword>
	<keyword>recurrent anal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage IV cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV vulvar cancer</keyword>
	<keyword>recurrent vulvar cancer</keyword>
	<keyword>stage IVA vaginal cancer</keyword>
	<keyword>stage IVB vaginal cancer</keyword>
	<keyword>recurrent vaginal cancer</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>recurrent gestational trophoblastic tumor</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>carcinoma appendix</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>recurrent carcinoma unknown primary</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>